دورية أكاديمية
أعرض في EDS

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.

التفاصيل البيبلوغرافية
العنوان: Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.
المؤلفون: Han EQ; Drexel University College of Medicine, Philadelphia, PA 19129, USA., Li XL, Wang CR, Li TF, Han SY
المصدر: Journal of hematology & oncology [J Hematol Oncol] 2013 Jul 08; Vol. 6, pp. 47. Date of Electronic Publication: 2013 Jul 08.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Biomed Central, 2008-
مواضيع طبية MeSH: Immunotherapy, Adoptive/*methods , Neoplasms/*immunology , Neoplasms/*therapy , Receptors, Antigen, T-Cell/*immunology , T-Lymphocytes/*immunology, Animals ; Humans ; Neoplasms/drug therapy ; Receptors, Antigen, T-Cell/genetics ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/immunology
مستخلص: Recent years have witnessed much progress in both basic research and clinical trials regarding cancer immunotherapy with chimeric antigen receptor (CAR)-engineered T cells. The unique structure of CAR endows T cell tumor specific cytotoxicity and resistance to immunosuppressive microenvironment in cancers, which helps patients to better tackle the issue of immunological tolerance. Adoptive immunotherapy (AIT) using this supernatural T cell have gained momentum after decades of intense debates because of the promising results obtained from preclinical models and clinical trials. However, it is very important for us to evaluate thoroughly the challenges/obstacles before widespread clinical application, which clearly warrants more studies to improve our understanding of the mechanism underlying AIT. In this review, we focus on the critical issues related to the clinical outcomes of CAR-based adoptive immunotherapy and discuss the rationales to refine this new cancer therapeutic modality.
References: J Exp Med. 2005 Oct 3;202(7):907-12. (PMID: 16203864)
N Engl J Med. 2011 Aug 25;365(8):725-33. (PMID: 21830940)
Mol Ther. 2009 Aug;17(8):1453-64. (PMID: 19384291)
Sci Transl Med. 2013 Mar 20;5(177):177ra38. (PMID: 23515080)
Int Immunol. 2003 Jan;15(1):49-58. (PMID: 12502725)
J Immunol. 2010 Jun 15;184(12):6938-49. (PMID: 20483753)
Mol Ther. 2007 Apr;15(4):825-33. (PMID: 17299405)
J Clin Oncol. 2008 Nov 10;26(32):5233-9. (PMID: 18809613)
Mol Ther. 2011 Dec;19(12):2133-43. (PMID: 21772253)
Nat Rev Clin Oncol. 2013 May;10(5):267-76. (PMID: 23546520)
Leuk Lymphoma. 2013 Feb;54(2):255-60. (PMID: 22897728)
Anticancer Res. 2012 Jun;32(6):2377-83. (PMID: 22641678)
Sci Transl Med. 2012 May 2;4(132):132ra53. (PMID: 22553251)
Immunotherapy. 2012 Sep;4(9):899-902. (PMID: 23046233)
Sci Transl Med. 2011 Aug 10;3(95):95ra73. (PMID: 21832238)
J Immunother. 2005 May-Jun;28(3):203-11. (PMID: 15838376)
Hum Gene Ther. 2012 Oct;23(10):1043-53. (PMID: 22780919)
Cancer Res. 2007 Nov 15;67(22):11029-36. (PMID: 18006849)
J Immunother. 2012 Nov-Dec;35(9):651-60. (PMID: 23090074)
Cancer Res. 2013 Jun 1;73(11):3371-80. (PMID: 23633494)
Exp Hematol. 2004 Jun;32(6):536-46. (PMID: 15183894)
Methods Mol Biol. 2012;907:645-66. (PMID: 22907378)
Hum Gene Ther. 2011 Dec;22(12):1575-86. (PMID: 21838572)
Mol Ther. 2010 Apr;18(4):843-51. (PMID: 20179677)
J Hematol Oncol. 2013 May 09;6:33. (PMID: 23656794)
J Immunother. 2012 Nov-Dec;35(9):689-701. (PMID: 23090078)
J Immunol. 2004 Jan 1;172(1):104-13. (PMID: 14688315)
Nat Med. 2004 Sep;10(9):942-9. (PMID: 15322536)
J Clin Invest. 2008 Jan;118(1):294-305. (PMID: 18060041)
Blood. 2011 Dec 1;118(23):6050-6. (PMID: 21984804)
Immunity. 2010 Jan 29;32(1):67-78. (PMID: 20060330)
Nat Biotechnol. 2013 Jan;31(1):71-5. (PMID: 23242161)
Mol Ther. 2013 Apr;21(4):904-12. (PMID: 23423337)
Blood. 2013 Feb 14;121(7):1165-74. (PMID: 23243285)
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2185-90. (PMID: 10681453)
Nat Med. 2011 Sep 18;17(10):1290-7. (PMID: 21926977)
Blood. 2012 Mar 22;119(12):2709-20. (PMID: 22160384)
Clin Cancer Res. 2011 Jul 1;17(13):4550-7. (PMID: 21498393)
Mol Ther. 2010 Apr;18(4):666-8. (PMID: 20357779)
J Immunother. 2013 Feb;36(2):112-23. (PMID: 23377665)
N Engl J Med. 2011 Nov 3;365(18):1673-83. (PMID: 22047558)
Cancer J. 2010 Jul-Aug;16(4):374-81. (PMID: 20693850)
J Immunol. 2006 May 1;176(9):5255-66. (PMID: 16621991)
J Gene Med. 2013 Feb;15(2):78-82. (PMID: 23322669)
J Clin Invest. 2011 May;121(5):1822-6. (PMID: 21540550)
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4. (PMID: 8421711)
Hum Gene Ther. 2010 Jan;21(1):75-86. (PMID: 19719389)
Gene Ther. 2010 Oct;17(10):1206-13. (PMID: 20555360)
Clin Dev Immunol. 2012;2012:238924. (PMID: 22481963)
N Engl J Med. 2013 Apr 18;368(16):1509-1518. (PMID: 23527958)
Clin Cancer Res. 2013 Jun 15;19(12):3153-64. (PMID: 23620405)
J Transl Med. 2012 Aug 03;10:157. (PMID: 22863016)
المشرفين على المادة: 0 (Receptors, Antigen, T-Cell)
0 (Recombinant Fusion Proteins)
تواريخ الأحداث: Date Created: 20130709 Date Completed: 20140505 Latest Revision: 20211021
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC3706354
DOI: 10.1186/1756-8722-6-47
PMID: 23829929
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا